Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (373)
NICE advice (1)
Quality standard (9)
Guidance programme
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (15)
Medical technologies guidance (13)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (295)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 371 to 380 of 383
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Technology appraisal guidance
TBC
Vibegron for treating symptoms of overactive bladder ID6300
Technology appraisal guidance
TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
Technology appraisal guidance
TBC
Voxelotor for treating sickle cell disease [ID1403]
Technology appraisal guidance
12 June 2024
VTS-270 for treating Niemann-Pick type C1 [ID1267]
Highly specialised technology
TBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
Technology appraisal guidance
22 November 2017
Women's and reproductive health guidelines
NICE guideline
TBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]
Technology appraisal guidance
TBC
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]
Technology appraisal guidance
17 July 2024
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Technology appraisal guidance
TBC
Previous page
1
…
36
37
Current page
38
39
Page
38
of
39
Next page
Results per page
10
25
50
All
Back to top